source
- Nuvig Therapeutics pauses CIDP trial of NVG-2089, cites enrollment and cost challengesNuvig Therapeutics, backed by major pharmaceutical partners, announced it is stopping development of its lead fusion protein NVG-2089 for chronic inflammatory demyelinating polyradiculoneuropathy (…
- Shionogi makes $2B rare disease play with IntraBio buyWith its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…BioSpace · 15d ago↗ source
- FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues